IVF Stock Overview

A life science portfolio company, develops clinical stage assets to treat patients with fertility, oncology, and autoimmune diseases. More details

IVF fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	1/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Revenue is forecast to grow 19.54% per year

Risk Analysis

Highly volatile share price over the past 3 months compared to the US market

Negative shareholders equity

Makes less than USD$1m in revenue ($0)

Does not have a meaningful market cap ($1M)

+ 3 more risks

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

INVO Fertility, Inc. Competitors

Escalon Medical

OTCPK:ESMC

US$1.4m

Helius Medical Technologies

NasdaqCM:HSDT

US$1.7m

Dynatronics

OTCPK:DYNT

US$1.1m

ENDRA Life Sciences

NasdaqCM:NDRA

US$1.8m

Price History & Performance

Summary of share price highs, lows and changes for INVO Fertility
Historical stock prices
Current Share Price	US$2.09
52 Week High	US$14.88
52 Week Low	US$1.38
Beta	0
1 Month Change	0.48%
3 Month Change	-55.82%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-82.92%

Recent updates

Shareholder Returns

	IVF	US Medical Equipment	US Market
7D	16.1%	0.09%	-0.3%
1Y	n/a	7.7%	8.1%

Return vs Industry: Insufficient data to determine how IVF performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how IVF performed against the US Market.

Price Volatility

Is IVF's price volatile compared to industry and market?
IVF volatility
IVF Average Weekly Movement	26.8%
Medical Equipment Industry Average Movement	9.7%
Market Average Movement	8.0%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	4.2%

Stable Share Price: IVF's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: IVF's weekly volatility has increased from 22% to 27% over the past year.

About the Company

Founded	Employees	CEO	Website
2007	n/a	Steve Shum	nayabiosciences.com

INVO Fertility, Inc., a life science portfolio company, develops clinical stage assets to treat patients with fertility, oncology, and autoimmune diseases. The company operates in two divisions, NAYA Women’s Health and NAYA Therapeutics. Its lead product includes NY-303, a GPC3-targeted FLEX-NK bispecific antibody that is in Phase I/II clinical trials for hepatocellular carcinoma, as well as solid and pediatric tumors; and NY-338, a CD38-targeted FLEX-NK bispecific antibody for multiple myeloma and autoimmune diseases.

INVO Fertility, Inc. Fundamentals Summary

How do INVO Fertility's earnings and revenue compare to its market cap?
IVF fundamental statistics
Market cap	US$1.39m
Earnings (TTM)	-US$14.86m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.1x

P/E Ratio

Is IVF overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IVF income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$14.86m
Earnings	-US$14.86m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-22.31
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	-88.6%

How did IVF perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/11 00:34
End of Day Share Price	2025/05/09 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

INVO Fertility, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jason McCarthy	Maxim Group